StockTipsArenaBeta

BUY Aurobindo Pharma — Rakesh Bansal

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byRakesh BansalHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via CNBC Awaaz.

Entry₹1,734.5Inferred
Target₹1,790
Total upside +3.20% (call closed)
Stop loss₹1,700-1.99% risk
Exit₹1,70022 Sept 2026, 9:30 am
Stop-loss hit-1.99%
Follow Rakesh Bansal for new calls(31% target hit, 269 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 204 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 22 Sept 2026
9 supporting1 opposing
Supports the BUY call (9)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Sept · yesterday

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 5d ago

(opens in new tab)

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 6d ago

(opens in new tab)

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 6d ago

(opens in new tab)

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Rakesh Bansal

Every call and its outcome